Hemostemix (CVE:HEM) Shares Cross Below 50 Day Moving Average – Here’s Why

Hemostemix Inc. (CVE:HEM)’s share price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$0.21 and traded as low as C$0.10. Hemostemix shares last traded at C$0.11, with a volume of 196,551 shares trading hands.

Hemostemix Stock Down 8.7 %

The firm has a market cap of C$15.30 million, a price-to-earnings ratio of -3.06 and a beta of 0.20. The stock’s 50 day moving average is C$0.21 and its 200 day moving average is C$0.13. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.

Insider Buying and Selling at Hemostemix

In other Hemostemix news, Director Peter Alan Lacey purchased 200,000 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was bought at an average cost of C$0.15 per share, with a total value of C$30,000.00. 10.43% of the stock is currently owned by corporate insiders.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.